Symposium
Unravelling the Pathways to Early Intervention in ATTR-CM
Chair: Julian Gillmore, London, UK
Faculty: Margot Davis, Vancouver, CA; Ahmad Masri, Portland, US
Overview
This interactive programme explores the critical steps in recognising and managing transthyretin amyloid cardiomyopathy (ATTR-CM) at an early stage. The expert faculty will share insights on current stabilising agents, examine disease progression trajectories and discuss emerging therapies. Gain practical insights into optimising patient outcomes through timely intervention and evolving management strategies.
Agenda
- Welcome and Introduction – Julian Gillmore, London, UK
- Case Study – Ahmad Masri, Portland, US
- Managing Disease Early – Julian Gillmore, London, UK
- ATTR Stabilisation: Current Standard of Care – Margot Davis, Vancouver, CA
- What Are Our Future Options? Panel Discussion and Q&A – All
Learning Objectives
- Review the binding affinity for current stabilising agents
- Recall the trajectory of disease progression in ATTR-CM
- Discuss future options for individuals who progress on treatment
This symposium is supported by an unrestricted educational grant from Bayer.
*Unravelling the Pathways to Early Intervention in ATTR-CM has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.
